Mr. Scott Boyes reports

MPX INTERNATIONAL' S WHOLLY-OWNED SUBSIDIARY, CANVEDA INC., ENTERS INTO AN AGREEMENT FOR THE MANUFACTURING AND DISTRIBUTION OF CANNABIS PRODUCTS IN ISRAEL

MPX International Corp.'s wholly owned subsidiary, Canveda Inc., a licence holder under the Cannabis Act (Canada), has entered into a production and distribution agreement with Panaxia Pharmaceutical Industries Israel Ltd., the largest manufacturer and distributor of medical cannabis products in Israel, for the packaging and distribution of cannabis which will be marketed and sold in Israel under Canveda's medical brand Salus BioPharma.

"MPXI has a long-standing relationship with Panaxia and welcomes the opportunity to market our brand in Israel as part of our international cannabis strategy," noted W. Scott Boyes, chairman, president and chief executive officer of MPX International. "Panaxia is a major player in the Israeli market and an emerging participant in the global cannabis space, and we are honoured to be able to work with them on this initial project."

A first shipment of 100 kilograms of high-quality cannabis flower will be shipped from Canada to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued.

Panaxia uses high-quality cannabis flower to manufacture and distribute a variety of standardized, pharmaceutical-grade, smokeless, measured-dosage cannabinoid-based products, including sublingual tablets, slow-release tablets, pastilles, rectal suppositories, vaginal suppositories, skin care ointments, topical patches and oral spray inhalers.

The Salus BioPharma products will be sold to patients with a variety of conditions such as PTSD (posttraumatic stress disorder), chronic pain, cancer, epilepsy, Parkinson's disease, Alzheimer's disease, anorexia and HIV/AIDS.

"We are proud to work on this project with our Canadian partners MPX International Corp. and expand our collaboration to the Israeli market. As an experienced pharmaceutical company and the largest manufacturer and distributor of medical cannabis products in Israel, we are committed to providing premium, standardized and scientifically backed pharmaceutical cannabis products to our partners and patients worldwide. MPXI leads the pharmaceutical approach to medical cannabis in Canada, which makes them a natural partner for distribution of high-quality pharmaceutical cannabis products in Israel," said Assi Rotbart, general manager of Panaxia.

"We will be shipping our initial 100 kilograms of bulk high-quality sativa and indica cannabis strains to test the market in Israel. Panaxia will be responsible for quality control, packaging and distribution of Salus BioPharma products," said Michael Arnkvarn, chief operating officer, Canada, of MPX. "The Salus BioPharma brand is our premier medical brand, and we are excited to commence international distribution of our Salus BioPharma products with Panaxia in Israel. Following this initial foray into the international cannabis market, we are working to expand distribution of the Salus BioPharma brand to additional international markets."

About MPX International Corp.

MPX International is a multinational diversified cannabis company focused on developing and operating assets across the international cannabis industry with an emphasis on cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. With current operations spanning four continents in Canada, Switzerland, South Africa, Malta and Australia as well as evolving partnership and distribution opportunities in other jurisdictions, MPX International continues to position itself as an emergent global participant in the cannabis industry.

We seek Safe Harbor.